A WALL STREET JOURNAL and USA TODAY NATIONAL BESTSELLER It's been said that true wealth is good health; and we couldn't agree more. Millions of people have awakened over the past few years from a nightmare in healthcare--a corrupt ecosystem designed to keep patients dependent and physicians beholden to corporations instead of patient care. We have a solution, and you're a part of it. The Wellness Company has brought together the brightest minds and bravest hearts in seven unique stories of courage, synchronicity, and hope. The Next Wave Is Brave illustrates to the reader the precise journey forward with tangible direction from the authors in the spirit of gratitude for the opportunity of our lifetime. Together, we can restore medical freedom. This book is our blueprint.

The story of doctors who developed a safe and effective early treatment for COVID-19 and their battle with the Bio-Pharmaceutical Complex that suppressed it. At the beginning of 2020, Dr. Peter McCullough was a highly regarded practicing physician, program director, teacher, and clinical investigator at a major academic medical center in Dallas, Texas. When COVID-19 arrived in March, he felt a duty to find a treatment for the disease. He wasn't alone. Other doctors all over the world were also searching for a cure. They followed the longstanding principle that it's best to tackle a sickness early, before it becomes life threatening. This is the story of how Dr. McCullough and his colleagues developed an early treatment protocol of generic, repurposed drugs and supplements that has saved millions of COVID-19 patients from hospitalization and death. In spite of their success, their early treatment protocol was not welcomed by public health officials. On the contrary, the news of their promising results was dismissed as soon as it was reported. At first this seemed like conventional skepticism, but then fraudulent papers maligning the protocol's repurposed drugs were published in academic medical journals. This and other acts of fraud revealed that a coordinated smear campaign against early treatment was being waged. Dr. McCullough and his colleagues soon found themselves censured, censored, attacked in the media, and fired from their jobs. The greatest victims of the smear campaign were COVID-19 patients who were consequently deprived of early treatment. Hundreds of thousands needlessly died of the disease. At the same time early treatment was suppressed, the US government and mainstream media proclaimed that the cure to COVID-19 lay in a new generation of vaccines that were being developed at warp speed. These were heralded as a forthcoming panacea that would save mankind and restore normalcy. As soon as they were mass deployed, public health officials would lift the restrictions on social and economic life. While many observers were thunderstruck by this turn of events, there were historical precedents. In his 1961 Farewell Address, President Eisenhower warned: We must guard against the acquisition of unwarranted influence, whether sought of unsought, by the military-industrial complex. The potential for the disastrous rise of misplaced power exists and will persist. We must never let the weight of this combination endanger our liberties or democratic processes. As Dr. McCullough and his colleagues learned, Eisenhower's warning has become equally applicable to the Bio-Pharmaceutical Complex of multinational drug companies, the NIH and other federal agencies, research and virology labs, and the Gates Foundation. Since COVID-19 arrived, this Complex has obtained misplaced power over every aspect of our lives and taken our liberties. The Courage to Face Covid-19 recounts how Dr. McCullough and his colleagues began their work by fighting a novel infectious disease, and then became leaders in fighting the tyrannical regime that endangers our American way of life.

This book is the first title that focuses exclusively on kidney disease and its impact in the cardiac catheterization laboratory. The increasing prevalence of vascular risk factors such as diabetes, obesity and hypertension coupled with increased longevity has resulted in a worldwide epidemic of cardiovascular and chronic kidney disease (CKD). Never has the impact of one organ system on the other been so profound, as in the current context of cardio-renal interactions. The cross talk between the heart and kidneys is highly relevant in the field of interventional cardiology, given the increasing number of trans-catheter procedures being performed in patients with underlying kidney disease. These procedures also have a significant impact on kidney function and require thoughtful interdisciplinary planning by a cardiorenal team, to achieve optimal outcomes This book assembles the collective expertise of several international leaders in the field of interventional cardiology and nephrology to summarize this complex interface. The book is divided into seven sections to comprehensively cover the topic, including sections on best practices with reduction of contrast associated acute kidney injury, cutting edge techniques to minimize kidney risk with complex interventions, impact of transcatheter valvular procedures on kidney function and the utility of cardio-nephrology teams . Less recognized complications with high morbidity such as athero-embolic renal disease are featured prominently, to increase awareness in the interventional cardiology and nephrology communities. This book is a valuable resource for interventional and structural cardiologists, general cardiologists and nephrologists dealing with the significant overlap areas between these two specialties. It is also relevant to medical students, trainee physicians in nephrology and cardiology, advanced care practitioners and nursing personnel in both specialties . Given the major impact of kidney function on outcomes in patients undergoing cardiac procedures, this textbook serves as a focal point to integrate relevant clinical data from both specialties and help interventional cardiologists achieve optimal outcomes, especially in patients with (or at risk for) kidney disease.

This textbook provides a practical and board-driven resource to describe and define the emerging field of cardiorenal medicine. Covering all aspects of the topic with depth and relevance, this groundbreaking reference brings together experts at the nexus between cardiovascular and renal medicine to provide an exception reference to educate in this critical area of modern medicine. It describes how the heart and kidneys are inextricably linked via hemodynamic, neural, hormonal and cellular signaling systems and, concentrating on disease-based coverage, goes on to review emerging concepts in epidemiology, pathogenesis, screening, diagnosis and the management of cardiorenal syndromes, all extensively illustrated and containing features to support scholarship in the field. Textbook of Cardiorenal Medicine provides consistent chapter organization, clear design and engaging text to define the diagnosis, treatment, intervention and surgical aspects of the full range of conditions encountered within this area of medicine. It is therefore an essential resource to all involved in the management of cardiorenal disease.